$IDXG Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERPACE BIOSCIENCES, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERPACE BIOSCIENCES, INC.. Get notifications about new insider transactions in INTERPACE BIOSCIENCES, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 25 2021 | IDXG | INTERPACE BIOSCIEN ... | Burnell Thomas W. | President & CEO | Buy | P | 8.68 | 10,855 | 94,221 | 10,855 | 0 to 10.9 K |
| Mar 12 2021 | IDXG | INTERPACE BIOSCIEN ... | Freeburg Thomas John | Chief Financial Off ... | Option Exercise | A | 6.00 | 50,000 | 300,000 | 50,000 | |
| Mar 12 2021 | IDXG | INTERPACE BIOSCIEN ... | Freeburg Thomas John | Chief Financial Off ... | Grant | A | 0.00 | 50,000 | 0 | 52,000 | 2 K to 52 K (+2,500.00 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.08 | 2,862 | 8,815 | 44,670 | 41.8 K to 44.7 K (+6.85 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.17 | 2,897 | 9,183 | 41,808 | 38.9 K to 41.8 K (+7.45 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.08 | 8,252 | 25,416 | 133,186 | 124.9 K to 133.2 K (+6.61 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.17 | 8,333 | 26,416 | 124,934 | 116.6 K to 124.9 K (+7.15 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.08 | 14,726 | 45,356 | 234,805 | 220.1 K to 234.8 K (+6.69 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.17 | 14,874 | 47,151 | 220,079 | 205.2 K to 220.1 K (+7.25 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.08 | 16,360 | 50,389 | 270,108 | 253.7 K to 270.1 K (+6.45 %) |
| Mar 01 2021 | IDXG | INTERPACE BIOSCIEN ... | Kamin Peter | 10% Owner | Buy | P | 3.17 | 14,946 | 47,379 | 253,748 | 238.8 K to 253.7 K (+6.26 %) |
| Dec 02 2020 | IDXG | INTERPACE BIOSCIEN ... | STOVER JACK E | Option Exercise | A | 6.00 | 43,750 | 262,500 | 43,750 | ||
| Dec 02 2020 | IDXG | INTERPACE BIOSCIEN ... | Burnell Thomas W. | President and CEO | Grant | A | 0.00 | 125,000 | 0 | 225,000 | 100 K to 225 K (+125.00 %) |
| Dec 02 2020 | IDXG | INTERPACE BIOSCIEN ... | Burnell Thomas W. | President and CEO | Grant | A | 0.00 | 100,000 | 0 | 225,000 | 125 K to 225 K (+80.00 %) |
| Jul 31 2020 | IDXG | INTERPACE BIOSCIEN ... | Early James | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Jul 31 2020 | IDXG | INTERPACE BIOSCIEN ... | Early James | Buy | M | 0.00 | 5,000 | 0 | 7,125 | 2.1 K to 7.1 K (+235.29 %) | |
| Jul 13 2020 | IDXG | INTERPACE BIOSCIEN ... | Gorman Robert J. | Director | Option Exercise | A | 5.21 | 77,000 | 401,170 | 77,000 | |
| Jul 13 2020 | IDXG | INTERPACE BIOSCIEN ... | Gorman Robert J. | Director | Option Exercise | A | 5.21 | 77,000 | 401,170 | 77,000 | |
| Jul 13 2020 | IDXG | INTERPACE BIOSCIEN ... | Gorman Robert J. | Director | Option Exercise | A | 5.21 | 89,000 | 463,690 | 89,000 | |
| Jul 13 2020 | IDXG | INTERPACE BIOSCIEN ... | Gorman Robert J. | Director | Option Exercise | A | 5.21 | 89,000 | 463,690 | 89,000 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | SULLIVAN STEPHEN J | Director | Option Exercise | A | 5.21 | 29,300 | 152,653 | 29,300 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | Rocca Fortunato R. | Director | Option Exercise | A | 5.21 | 28,000 | 145,880 | 28,000 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | KEEGAN JOSEPH D | Director | Option Exercise | A | 5.21 | 29,000 | 151,090 | 29,000 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | SULLIVAN STEPHEN J | Director | Option Exercise | A | 5.21 | 29,300 | 152,653 | 29,300 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | Rocca Fortunato R. | Director | Option Exercise | A | 5.21 | 28,000 | 145,880 | 28,000 | |
| Jul 10 2020 | IDXG | INTERPACE BIOSCIEN ... | KEEGAN JOSEPH D | Director | Option Exercise | A | 5.21 | 29,000 | 151,090 | 29,000 | |
| Apr 06 2020 | IDXG | INTERPACE BIOSCIEN ... | STOVER JACK E | President and CEO | Grant | A | 0.00 | 7,188 | 0 | 30,271 | 23.1 K to 30.3 K (+31.14 %) |
| Feb 04 2020 | IDXG | INTERPACE BIOSCIEN ... | Lampe-Onnerud Christina | Director | Grant | A | 0.00 | 2,391 | 0 | 2,391 | 0 to 2.4 K |
| Feb 04 2020 | IDXG | INTERPACE BIOSCIEN ... | Marcet Pablo | Director | Grant | A | 0.00 | 2,391 | 0 | 2,391 | 0 to 2.4 K |
| Feb 03 2020 | IDXG | INTERPACE BIOSCIEN ... | Knechtel Fred S. | Chief Financial Off ... | Option Exercise | A | 7.91 | 60,000 | 474,600 | 60,000 | |
| Jan 31 2020 | IDXG | INTERPACE BIOSCIEN ... | Gorman Robert J. | Director | Grant | A | 7.91 | 6,321 | 49,999 | 6,321 | 0 to 6.3 K |
| Jan 31 2020 | IDXG | INTERPACE BIOSCIEN ... | Early James | Chief Financial Off ... | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| Jan 24 2020 | IDXG | INTERPACE BIOSCIEN ... | STOVER JACK E | President and CEO | Option Exercise | A | 8.18 | 35,000 | 286,300 | 35,000 | |
| Jan 24 2020 | IDXG | INTERPACE BIOSCIEN ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | A | 8.18 | 7,500 | 61,350 | 7,500 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | McCarthy Laurence | Director | Option Exercise | A | 6.00 | 1,000 | 6,000 | 28,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | McCarthy Laurence | Director | Option Exercise | A | 6.00 | 27,000 | 162,000 | 27,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | McCarthy Laurence | Director | Option Exercise | D | 8.00 | 270 | 2,160 | 0 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Lev Eric B. | Director | Option Exercise | A | 6.00 | 1,000 | 6,000 | 28,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Lev Eric B. | Director | Option Exercise | A | 6.00 | 27,000 | 162,000 | 27,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Lev Eric B. | Director | Option Exercise | D | 8.00 | 270 | 2,160 | 0 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | A | 6.00 | 1,000 | 6,000 | 28,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | A | 6.00 | 27,000 | 162,000 | 27,000 | |
| Jan 17 2020 | IDXG | INTERPACE BIOSCIEN ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | D | 8.00 | 270 | 2,160 | 0 | |
| Oct 18 2019 | IDXG | Interpace Diagnost ... | Lev Eric B. | Director | Option Exercise | A | 0.80 | 130 | 104 | 270 | |
| Oct 18 2019 | IDXG | Interpace Diagnost ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | A | 0.80 | 130 | 104 | 270 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Lev Eric B. | Director | Option Exercise | D | 0.00 | 80 | 0 | 0 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Lev Eric B. | Director | Option Exercise | A | 0.80 | 80 | 64 | 140 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Lev Eric B. | Director | Option Exercise | D | 0.00 | 80 | 0 | 0 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Lev Eric B. | Director | Option Exercise | A | 0.80 | 80 | 64 | 140 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | D | 0.00 | 80 | 0 | 0 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | A | 0.80 | 80 | 64 | 140 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | D | 0.00 | 80 | 0 | 0 | |
| Oct 15 2019 | IDXG | Interpace Diagnost ... | Ampersand 2018 Limited Partner ... | 10% Owner | Option Exercise | A | 0.80 | 80 | 64 | 140 | |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Freeburg Thomas John | Chief Accounting Of ... | Option Exercise | A | 0.98 | 8,000 | 7,840 | 8,000 | |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Freeburg Thomas John | Chief Accounting Of ... | Grant | A | 0.00 | 2,000 | 0 | 2,000 | 0 to 2 K |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 0.98 | 347,688 | 340,734 | 347,688 | |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Grant | A | 0.00 | 86,922 | 0 | 427,300 | 340.4 K to 427.3 K (+25.54 %) |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | A | 0.98 | 158,112 | 154,950 | 158,112 | |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Grant | A | 0.00 | 39,528 | 0 | 84,169 | 44.6 K to 84.2 K (+88.55 %) |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 0.98 | 105,360 | 103,253 | 105,360 | |
| Mar 15 2019 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Grant | A | 0.00 | 26,340 | 0 | 43,340 | 17 K to 43.3 K (+154.94 %) |
| Dec 06 2018 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 1.08 | 15,000 | 16,200 | 15,000 | |
| Dec 06 2018 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | A | 1.08 | 67,000 | 72,360 | 67,000 | |
| Dec 06 2018 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 1.08 | 375,000 | 405,000 | 375,000 | |
| Dec 06 2018 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Grant | A | 0.00 | 60,000 | 0 | 313,378 | 253.4 K to 313.4 K (+23.68 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Option Exercise | A | 1.01 | 19,200 | 19,392 | 19,200 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Grant | A | 0.00 | 4,800 | 0 | 24,583 | 19.8 K to 24.6 K (+24.26 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 1.01 | 224,000 | 226,240 | 224,000 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Grant | A | 0.00 | 56,000 | 0 | 75,738 | 19.7 K to 75.7 K (+283.72 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | KEEGAN JOSEPH D | Director | Option Exercise | A | 1.01 | 19,200 | 19,392 | 19,200 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | KEEGAN JOSEPH D | Director | Grant | A | 0.00 | 4,800 | 0 | 17,569 | 12.8 K to 17.6 K (+37.59 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Schnoll-Sussman Felice | Director | Option Exercise | A | 1.01 | 19,200 | 19,392 | 19,200 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Schnoll-Sussman Felice | Director | Grant | A | 0.00 | 4,800 | 0 | 4,800 | 0 to 4.8 K |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | A | 1.01 | 112,000 | 113,120 | 112,000 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | M | 0.00 | 2,000 | 0 | 2,000 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Grant | A | 0.00 | 28,000 | 0 | 31,241 | 3.2 K to 31.2 K (+863.93 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Buy | M | 0.00 | 2,000 | 0 | 3,241 | 1.2 K to 3.2 K (+161.16 %) |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 1.01 | 56,000 | 56,560 | 56,000 | |
| Mar 09 2018 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Grant | A | 0.00 | 14,000 | 0 | 14,000 | 0 to 14 K |
| Sep 27 2017 | IDXG | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 1.45 | 345,000 | 500,250 | 345,000 | |
| Sep 27 2017 | IDXG | Interpace Diagnost ... | Richard Gregory | Chief Commerical Of ... | Option Exercise | A | 1.45 | 200,000 | 290,000 | 200,000 | |
| Sep 27 2017 | IDXG | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 1.45 | 40,000 | 58,000 | 40,000 | |
| Sep 26 2017 | IDXG | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Option Exercise | A | 1.48 | 13,000 | 19,240 | 13,000 | |
| Sep 26 2017 | IDXG | Interpace Diagnost ... | KEEGAN JOSEPH D | Director | Option Exercise | A | 1.48 | 10,000 | 14,800 | 10,000 | |
| Sep 26 2017 | IDXG | Interpace Diagnost ... | Schnoll-Sussman Felice | Director | Option Exercise | A | 1.48 | 20,000 | 29,600 | 20,000 | |
| Mar 20 2017 | PDII | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 2.12 | 134,602 | 285,356 | 134,602 | |
| Mar 20 2017 | PDII | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 2.12 | 14,475 | 30,687 | 14,475 | |
| Oct 19 2016 | PDII | Interpace Diagnost ... | Early James | Chief Financial Off ... | Option Exercise | A | 0.16 | 80,000 | 12,800 | 80,000 | |
| Oct 18 2016 | PDII | Interpace Diagnost ... | STOVER JACK E | President and CEO | Option Exercise | A | 0.16 | 326,368 | 52,219 | 326,368 | |
| Mar 03 2016 | PDII | Interpace Diagnost ... | Krishnamurti Nat | Interim CFO | Option Exercise | A | 0.00 | 60,000 | 0 | 60,000 | |
| Feb 05 2016 | PDII | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Grant | A | 0.47 | 100,000 | 47,000 | 197,828 | 97.8 K to 197.8 K (+102.22 %) |
| Feb 05 2016 | PDII | Interpace Diagnost ... | STOVER JACK E | Interim President a ... | Grant | A | 0.53 | 100,000 | 53,000 | 197,378 | 97.4 K to 197.4 K (+102.69 %) |
| Feb 05 2016 | PDII | Interpace Diagnost ... | KEEGAN JOSEPH D | Director | Grant | A | 0.47 | 127,696 | 60,017 | 127,696 | 0 to 127.7 K |
| Feb 05 2016 | PDII | Interpace Diagnost ... | Glorikian Harry | Director | Grant | A | 0.47 | 127,696 | 60,017 | 127,696 | 0 to 127.7 K |
| Dec 30 2015 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Payment of Exercise | F | 0.53 | 69,020 | 36,581 | 142,852 | 211.9 K to 142.9 K (-32.58 %) |
| Dec 04 2015 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Sell | S | 0.77 | 1,748 | 1,346 | 130,173 | 131.9 K to 130.2 K (-1.33 %) |
| Dec 04 2015 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Sell | S | 0.80 | 765 | 612 | 131,921 | 132.7 K to 131.9 K (-0.58 %) |
| Dec 04 2015 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Sell | S | 0.78 | 4,262 | 3,324 | 132,686 | 136.9 K to 132.7 K (-3.11 %) |
| Jun 04 2015 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Grant | A | 1.32 | 45,455 | 60,001 | 143,086 | 97.6 K to 143.1 K (+46.56 %) |
| Jun 04 2015 | PDII | Interpace Diagnost ... | Dreismann Heiner | Director | Grant | A | 1.32 | 34,091 | 45,000 | 50,177 | 16.1 K to 50.2 K (+211.93 %) |
| Jun 04 2015 | PDII | Interpace Diagnost ... | FEDERSPIEL JOHN | Director | Grant | A | 1.32 | 34,091 | 45,000 | 100,378 | 66.3 K to 100.4 K (+51.43 %) |
| Jun 04 2015 | PDII | Interpace Diagnost ... | STOVER JACK E | Director | Grant | A | 1.32 | 34,091 | 45,000 | 97,378 | 63.3 K to 97.4 K (+53.87 %) |
| Jun 04 2015 | PDII | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Grant | A | 1.32 | 34,091 | 45,000 | 97,828 | 63.7 K to 97.8 K (+53.49 %) |
| Mar 09 2015 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Grant | A | 1.73 | 444,364 | 768,750 | 871,681 | 427.3 K to 871.7 K (+103.99 %) |
| Feb 26 2015 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Grant | A | 1.85 | 91,217 | 168,751 | 136,948 | 45.7 K to 136.9 K (+199.46 %) |
| Feb 26 2015 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Grant | A | 1.85 | 147,973 | 273,750 | 211,872 | 63.9 K to 211.9 K (+231.57 %) |
| Nov 25 2014 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Buy | P | 1.65 | 21,400 | 35,310 | 63,899 | 42.5 K to 63.9 K (+50.35 %) |
| Nov 25 2014 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Buy | P | 1.65 | 600 | 990 | 42,499 | 41.9 K to 42.5 K (+1.43 %) |
| Nov 12 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.69 | 16,000 | 27,090 | 533,317 | 517.3 K to 533.3 K (+3.09 %) |
| Nov 12 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.77 | 33,000 | 58,502 | 517,317 | 484.3 K to 517.3 K (+6.81 %) |
| Nov 12 2014 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | VP of Corporate Dev ... | Buy | P | 1.50 | 200 | 300 | 467,194 | 467 K to 467.2 K (+0.04 %) |
| Nov 12 2014 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | VP of Corporate Dev ... | Buy | P | 1.75 | 199,800 | 349,650 | 466,994 | 267.2 K to 467 K (+74.78 %) |
| Nov 10 2014 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Buy | P | 1.58 | 5,000 | 7,900 | 50,224 | 45.2 K to 50.2 K (+11.06 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Buy | P | 1.71 | 57,300 | 98,092 | 154,931 | 97.6 K to 154.9 K (+58.69 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.60 | 1,000 | 1,600 | 490,403 | 489.4 K to 490.4 K (+0.20 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.72 | 500 | 860 | 489,403 | 488.9 K to 489.4 K (+0.10 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.72 | 500 | 860 | 488,903 | 488.4 K to 488.9 K (+0.10 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.75 | 27,500 | 48,078 | 488,403 | 460.9 K to 488.4 K (+5.97 %) |
| Nov 07 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Buy | P | 1.74 | 27,500 | 47,737 | 460,903 | 433.4 K to 460.9 K (+6.35 %) |
| Oct 22 2014 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Option Exercise | A | 1.79 | 117,187 | 209,765 | 117,187 | |
| Oct 22 2014 | PDII | Interpace Diagnost ... | Miao Graham G | CFO | Grant | A | 1.79 | 41,899 | 74,999 | 41,899 | 0 to 41.9 K |
| Aug 15 2014 | PDII | Interpace Diagnost ... | Dreismann Heiner | Director | Grant | A | 3.73 | 16,086 | 60,001 | 16,086 | 0 to 16.1 K |
| Jun 05 2014 | PDII | Interpace Diagnost ... | Climaco John M | Director | Grant | A | 4.52 | 9,956 | 45,001 | 21,539 | 11.6 K to 21.5 K (+85.95 %) |
| Jun 05 2014 | PDII | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Grant | A | 4.52 | 9,956 | 45,001 | 63,737 | 53.8 K to 63.7 K (+18.51 %) |
| Jun 05 2014 | PDII | Interpace Diagnost ... | STOVER JACK E | Director | Grant | A | 4.52 | 9,956 | 45,001 | 63,287 | 53.3 K to 63.3 K (+18.67 %) |
| Jun 05 2014 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Grant | A | 4.52 | 13,274 | 59,998 | 97,631 | 84.4 K to 97.6 K (+15.74 %) |
| Jun 05 2014 | PDII | Interpace Diagnost ... | FEDERSPIEL JOHN | Director | Grant | A | 4.52 | 9,956 | 45,001 | 66,287 | 56.3 K to 66.3 K (+17.67 %) |
| Mar 27 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Payment of Exercise | F | 4.91 | 23,316 | 114,482 | 433,403 | 456.7 K to 433.4 K (-5.11 %) |
| Feb 28 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Option Exercise | A | 5.10 | 188,165 | 959,642 | 678,116 | |
| Feb 28 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Option Exercise | A | 5.10 | 177,665 | 906,092 | 489,951 | |
| Feb 28 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Grant | A | 5.10 | 63,177 | 322,203 | 456,719 | 393.5 K to 456.7 K (+16.05 %) |
| Feb 28 2014 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Grant | A | 5.10 | 10,584 | 53,978 | 393,542 | 383 K to 393.5 K (+2.76 %) |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Option Exercise | A | 5.13 | 57,107 | 292,959 | 108,949 | |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Grant | A | 5.13 | 20,270 | 103,985 | 46,598 | 26.3 K to 46.6 K (+76.99 %) |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Melillo Gerald R JR | President, Sales Se ... | Grant | A | 5.13 | 1,904 | 9,768 | 26,328 | 24.4 K to 26.3 K (+7.80 %) |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | CFO | Option Exercise | A | 5.13 | 88,832 | 455,708 | 249,381 | |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | CFO | Grant | A | 5.13 | 31,532 | 161,759 | 267,194 | 235.7 K to 267.2 K (+13.38 %) |
| Feb 27 2014 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | CFO | Grant | A | 5.13 | 4,221 | 21,654 | 235,662 | 231.4 K to 235.7 K (+1.82 %) |
| Nov 19 2013 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Buy | P | 5.25 | 13,000 | 68,250 | 84,357 | 71.4 K to 84.4 K (+18.22 %) |
| Nov 19 2013 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Buy | P | 5.14 | 7,400 | 38,036 | 71,357 | 64 K to 71.4 K (+11.57 %) |
| Nov 04 2013 | PDII | Interpace Diagnost ... | Climaco John M | Director | Grant | A | 5.18 | 11,583 | 60,000 | 11,583 | 0 to 11.6 K |
| Jun 06 2013 | PDII | Interpace Diagnost ... | SULLIVAN STEPHEN J | Director | Grant | A | 4.47 | 10,068 | 45,004 | 53,781 | 43.7 K to 53.8 K (+23.03 %) |
| Jun 06 2013 | PDII | Interpace Diagnost ... | LUBATKIN VERONICA | Director | Grant | A | 4.47 | 10,068 | 45,004 | 54,137 | 44.1 K to 54.1 K (+22.85 %) |
| Jun 06 2013 | PDII | Interpace Diagnost ... | STOVER JACK E | Director | Grant | A | 4.47 | 10,068 | 45,004 | 53,331 | 43.3 K to 53.3 K (+23.27 %) |
| Jun 06 2013 | PDII | Interpace Diagnost ... | FEDERSPIEL JOHN | Director | Grant | A | 4.47 | 10,068 | 45,004 | 56,331 | 46.3 K to 56.3 K (+21.76 %) |
| Jun 06 2013 | PDII | Interpace Diagnost ... | Belle Gerald P. | Director | Grant | A | 4.47 | 13,423 | 60,001 | 63,957 | 50.5 K to 64 K (+26.56 %) |
| Apr 08 2013 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Option Exercise | A | 5.44 | 141,700 | 770,848 | 592,286 | |
| Apr 08 2013 | PDII | Interpace Diagnost ... | Lurker Nancy | CEO | Grant | A | 5.44 | 51,320 | 279,181 | 382,958 | 331.6 K to 383 K (+15.47 %) |
| Apr 08 2013 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | CFO | Option Exercise | A | 5.44 | 70,850 | 385,424 | 202,076 | |
| Apr 08 2013 | PDII | Interpace Diagnost ... | Smith Jeffrey Edward | CFO | Grant | A | 5.44 | 25,660 | 139,590 | 231,441 | 205.8 K to 231.4 K (+12.47 %) |